Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.

doi:10.1038/s41379-020-0618-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Jan 2021

Kang Eun Young, Cheasley Dane, LePage Cecile, Wakefield Matthew J, da Cunha Torres Michelle, Rowley Simone, Salazar Carolina, Xing Zhongyue, Allan Prue, Bowtell David D L, Mes-Masson Anne-Marie, Provencher Diane M, Rahimi Kurosh, Kelemen Linda E, Fasching Peter A, Doherty Jennifer A, Goodman Marc T, Goode Ellen L, Deen Suha, Pharoah Paul D P, Brenton James D, Sieh Weiva, Mateoiu Constantina, Sundfeldt Karin, Cook Linda S, Le Nhu D, Anglesio Michael S, Gilks C Blake, Huntsman David G, Kennedy Catherine J, Traficante Nadia, DeFazio Anna, Kaufmann Scott, Churchman Michael, Gourley Charlie, Stephens Andrew N, Meagher Nicola S, Ramus Susan J, Antill Yoland C, Campbell Ian, Scott Clare L, Köbel Martin, Gorringe Kylie L

Abstract excerpt

TP53 mutations are implicated in the progression of mucinous borderline tumors (MBOT) to mucinous ovarian carcinomas (MOC). Optimized immunohistochemistry (IHC) for TP53 has been established as a proxy for the TP53 mutation status in other ovarian tumor types. We aimed to confirm the ability of TP53 IHC to predict TP53 mutation status in ovarian mucinous tumors and to evaluate the association of TP53 mutation...

Topics

Adult
Australia
Biomarkers, Tumor
DNA Mutational Analysis
Female

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Humans

Immunohistochemistry

Middle Aged

Mutation

Neoplasms, Cystic, Mucinous, and Serous

North America

Observer Variation

Ovarian Neoplasms

Predictive Value of Tests

Prognosis

Reproducibility of Results

Risk Assessment

Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 32724153
DOI: 10.1038/s41379-020-0618-9
PMCID: PMC9704519

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.